NEGLECTED DISEASE RESEARCH & DEVELOPMENT: THE PUBLIC DIVIDE - - PowerPoint PPT Presentation

▶

Jun 22, 2023 177 likes •399 views

NEGLECTED DISEASE RESEARCH & DEVELOPMENT: THE PUBLIC DIVIDE Policy Cures Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the

SLIDE 1

NEGLECTED DISEASE RESEARCH & DEVELOPMENT: THE PUBLIC DIVIDE

SLIDE 2

Policy Cures

Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world

SLIDE 3

Annual survey of global investment into R&D of

new neglected disease products

Neutral, comparable, comprehensive analysis
Commissioned by the Bill & Melinda Gates

Foundation

G-FINDER OVERVIEW

SLIDE 4

31 neglected diseases
134 product areas
All R&D stages
Data from 201 organisations
Over 9,000 entries

G-FINDER SCOPE & METHODOLOGY

SLIDE 5

Findings OVERALL

$3,165m

invested into R&D for new neglected disease products in 2012

SLIDE 6

$92.1m higher in 2012 than in 2011 Findings OVERALL

$2.4bn bn $2.8bn bn $3.0bn n $2.9bn bn $2.9bn n $3.0bn bn 20 2007 07 20 2008 08 20 2009 09 20 2010 10 20 2011 11 20 2012 12

SLIDE 7

Findings DISEASES

Top tier diseases

HIV/AIDS (↑ $37.8m) TB (↓ $32.5m) Malaria (↓ $22.3m) 10 10 20 20 30 30 40 40 50 50 60 60 70 70 80 80 90 90 10 100 $0 $0 $5 $500 00 $1 $1,000 00 $1 $1,500 00 $2 $2,000 00 $2 $2,500 00 $3 $3,000 00

2007 2008^ 2009^ 2010^ 2011^ 2012^

% of funding ding Milli lion

ns ($)

SLIDE 8

Findings DISEASES

Second tier diseases

Dengue (↑ $17.7m) Salmonella infections (↑ $6.7m) Helminth infections (↑ $5.1m) Diseases with stable funding: Diarrhoeal diseases Bacterial pneumonia & meningitis Kinetoplastids 10 10 20 20 30 30 40 40 50 50 60 60 70 70 80 80 90 90 10 100 $0 $0 $5 $500 00 $1 $1,000 00 $1 $1,500 00 $2 $2,000 00 $2 $2,500 00 $3 $3,000 00

2007 2008^ 2009^ 2010^ 2011^ 2012^

% of funding ding Milli lion

ns ($)

SLIDE 9

Findings DISEASES

Third tier diseases

Leprosy (↑ $6.1m) Diseases with stable funding: Trachoma Rheumatic fever Buruli ulcer 10 10 20 20 30 30 40 40 50 50 60 60 70 70 80 80 90 90 10 100 $0 $0 $5 $500 00 $1 $1,000 00 $1 $1,500 00 $2 $2,000 00 $2 $2,500 00 $3 $3,000 00

2007 2008^ 2009^ 2010^ 2011^ 2012^

% of funding ding Milli lion

ns ($)

SLIDE 10

All sectors increased funding in 2012

Findings FUNDERS

Private te $527.2m 2m Phila lanth nthrop ropic ic $631.0m .0m Public ic $2.0b 0bn $12.4m $51.9m $27.8m Pri rivate te Phila ilanthr nthropic ic Pub ublic lic

SLIDE 11

Public funding up $27.8m … (but more later)

Findings PUBLIC FUNDING

$1 $1,550 50 $1 $1,600 00 $1 $1,650 50 $1 $1,700 00 $1 $1,750 50 $1 $1,800 00 $1 $1,850 50 $1 $1,900 00 $1 $1,950 50 $2 $2,000 00 $2 $2,050 50 20 2007 07 20 2008 08 20 2009 09 20 2010 10 20 2011 11 20 2012 12 Milli lion

$24.8m $9.3m 3m

$6.4m

4m Multi ltilat latera rals ls

SLIDE 12

Philanthropic funding up $51.9m Entirely due to the Wellcome Trust (up $53.0m)

Findings PHILANTHROPIC FUNDING

$0 $0 $1 $100 00 $2 $200 00 $3 $300 00 $4 $400 00 $5 $500 00 $6 $600 00 $7 $700 00 $8 $800 00 20 2007 07 20 2008 08 20 2009 09 20 2010 10 20 2011 11 20 2012 12 Milli lion

SLIDE 13

Industry funding up $12.4m

Findings INDUSTRY FUNDING

$0 $0 $1 $100 00 $2 $200 00 $3 $300 00 $4 $400 00 $5 $500 00 $6 $600 00 20 2007 07 20 2008 08 20 2009 09 20 2010 10 20 2011 11 20 2012 12 Milli lions ns Indu ndustry try MNCs MNCs SMEs MEs

SLIDE 14

Findings TOP FUNDERS

Funde der 2012 12 US$ $ (milli llions) s) 2012 12 percen centage tage of total l (%) %)

US NIH 1,278.2 40.4 Aggregate industry 527.2 16.7 Gates Foundation 444.1 14.0 Wellcome Trust 147.8 4.7 European Commission 93.1 2.9 USAID 82.2 2.6 US DOD 74.8 2.4 UK MRC 47.7 1.5 UK DFID 45.4 1.4 Inserm 39.9 1.3 Australian NHMRC 29.4 0.9 Institut Pasteur 22.3 0.7

Subtotal top 12 funders 2,832.1 89.5

SLIDE 15

The biggest decrease yet in PDP funding – down $87.4m (-20%)

Findings PDP FUNDING

$104.7m 7m

$38.2m

$37.3m

$34.7m

$87.4m

.4m 2009 2009 2010 2010 2011 2011 2012 2012

SLIDE 16

Public pullback from neglected disease R&D funding 20% (ex-US) since financial crisis

Discussion

50%

$0 $0 $5 $50 $1 $100 00 $1 $150 50 $2 $200 00 $2 $250 50 $3 $300 00 $3 $350 50 $4 $400 00 $4 $450 50 $5 $500 00

$1,100 $1,150 $1,200 $1,250 $1,300 $1,350 $1,400 $1,450 $1,500

2007 2008^ 2009^ 2010^ 2011^ 2012^

Non Non-US US HIC public fundi ding ng (millions lions) US public lic funding ding (millions llions) US US HIC pub public lic fund unders rs (exc xclud luding ing US US)

SLIDE 17

Discussion

50%

27.4% 4%

1.8%

8% Prod

uct t developm

pment

Funding for product development still declining 2007-2012

SLIDE 18

Every sector cut their PDP funding in 2012

Discussion

PDP funding 2007-2012

$0 $0 $5 $50 $1 $100 00 $1 $150 50 $2 $200 00 $2 $250 50 $3 $300 00 $3 $350 50 $4 $400 00 20 2007 07 20 2008 08 20 2009 09 20 2010 10 20 2011 11 20 2012 12 Milli lion

Phila ilanthr nthropic ic Gat Gates Foundat Foundation ion Ai Aid d agenc gencie ies Scienc nce & & technol nology

gy agenc

ncies ies

SLIDE 19

The public sector drives R&D funding (two-thirds) … what governments do matters
The US Government is holding the funding line – other governments are not
Growing gap between government funding for academic research and product development

The public divide

SLIDE 20

Download the full report at www.policycures.org/g-finder2013.html